<DOC>
	<DOCNO>NCT01460472</DOCNO>
	<brief_summary>This prospective , randomize , open label , parallel-group , multicenter phase III study evaluate efficacy safety active specific immunotherapy racotumomab plus best supportive care versus best supportive care patient advance NSCLC achieve Objective Response ( Partial Complete Response ) Stable Disease standard first-line treatment . Also immunological parameter evaluate . Best supportive therapy administer patient study accord institutional standard include subsequent onco-specific therapy . 1082 patient include study , non-small cell lung cancer stage IIIA ( non-resectable ) , IIIB IV .</brief_summary>
	<brief_title>Immunotherapy With Racotumomab Advanced Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Voluntarily sign informed consent . 2 . Cytologic histologically diagnose NSCLC stage IIIA ( nonresectable ) IIIB IV ( TNM ) . 3 . In continuous complete partial remission stable disease accord Response Evaluation Criteria Solid Tumours ( RECIST ) standard firstline treatment . 4 . Imaging study document response firstline therapy must available evaluation investigator . 5 . Time lapse 21 56 day end oncospecific treatment start vaccination . Patients must recover acute toxicity produce previous therapy . 6 . Age great equal 18 year , either sex . 7 . Eastern Cooperative Oncology Group performance status less 2 . 8 . Adequate organ function , define follow : 8.1 . Electrocardiogram ( ECG ) without significant anomaly , perform 7 day precede entry 8.2 . Haemoglobin great equal 90 g/L 8.3 . Total white blood cell count ( WBC ) great equal 3.0 x 10^9/L 8.4 . Absolute neutrophil count ( ANC ) great equal 1.5 x 10^9/L 8.5 . Platelet count great 100 x 10^9/L 8.6 . Total bilirubin less equal 1.5 fold maximum normal value place evaluation 2.5 fold maximum normal value case liver metastases 8.7 . Glutamicoxaloacetic transaminase/aspartate aminotransferase ( GOT/AST ) , glutamicpyruvic transaminase/alanine aminotransferase ( GPT/ALT ) , less equal 2.5 fold maximum normal value place evaluation ( case liver metastasis , less 5 fold maximum normal value ) 8.8 . Creatinine le equal 2 mg/dL ( less equal 176 Âµmol/L ) 9 . Known hepatitis B virus carrier liver function test within accepted limit eligible 1 . Pregnant breastfeeding patient 2 . Known hypersensitivity component formulation 3 . Fertile patient either sex use adequate contraceptive method treatment 4 . Disease progression prior randomization 5 . Recurrent NSCLC , relapse le one year complete curative intent therapy 6 . Patients receive investigational medication ( include investigational immunotherapy NSCLC ) receive medication within 30 day enter protocol 7 . Autoimmune diseases chronic decompensated disease 8 . Acute allergic disorder history severe allergic reaction 9 . Known brain metastasis 10 . History demyelinate disease inflammatory disease central nervous system peripheral nervous system 11 . Noncontrolled intercurrent disease , include active infection , symptomatic congestive heart failure , unstable chest angina heart arrhythmia , well mentally incapable patient 12 . Other malignant disease except non melanoma skin cancer , situ carcinoma cervix , incidental prostate cancer ( T1a , Gleason le equal 6 , prostate specific antigen ( PSA ) less 0.5 ng/ml ) tumour receive adequate treatment evidence diseasefree period great equal 5 year 13 . Receiving chronic therapy 10 day dose prednisone great 10 mg/day ( equivalent ) moment inclusion . Inhaled topical corticosteroid allow . 14 . Active hepatitis C positive test human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Lung cancer , small-cell</keyword>
	<keyword>advanced lung cancer</keyword>
	<keyword>therapeutic vaccine</keyword>
	<keyword>anti-idiotypic vaccine</keyword>
	<keyword>1E10</keyword>
</DOC>